{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:55:21Z","timestamp":1793912121030,"version":"4.8.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000069","name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K01AR073923"],"award-info":[{"award-number":["K01AR073923"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["R03DE029873"],"award-info":[{"award-number":["R03DE029873"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Oral Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    X-linked hypophosphatemia (XLH) is a rare disease of elevated fibroblast growth factor 23 (FGF23) production that leads to hypophosphatemia and impaired mineralization of bone and teeth. The clinical manifestations of XLH include a high prevalence of dental abscesses and periodontal disease, likely driven by poorly formed structures of the dentoalveolar complex, including the alveolar bone, cementum, dentin, and periodontal ligament. Our previous studies have demonstrated that sclerostin antibody (Scl-Ab) treatment improves phosphate homeostasis, and increases long bone mass, strength, and mineralization in the\n                    <jats:italic>Hyp<\/jats:italic>\n                    mouse model of XLH. In the current study, we investigated whether Scl-Ab impacts the dentoalveolar structures of\n                    <jats:italic>Hyp<\/jats:italic>\n                    mice. Male and female wild-type and\n                    <jats:italic>Hyp<\/jats:italic>\n                    littermates were injected with 25\u2009mg\u00b7kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    of vehicle or Scl-Ab twice weekly beginning at 12 weeks of age and euthanized at 20 weeks of age. Scl-Ab increased alveolar bone mass in both male and female mice and alveolar tissue mineral density in the male mice. The positive effects of Scl-Ab were consistent with an increase in the fraction of active (nonphosphorylated) \u03b2-catenin, dentin matrix protein 1 (DMP1) and osteopontin stained alveolar osteocytes. Scl-Ab had no effect on the mass and mineralization of dentin, enamel, acellular or cellular cementum. There was a nonsignificant trend toward increased periodontal ligament (PDL) attachment fraction within the Hyp mice. Additional PDL fiber structural parameters were not affected by Scl-Ab. The current study demonstrates that Scl-Ab can improve alveolar bone in adult\n                    <jats:italic>Hyp<\/jats:italic>\n                    mice.\n                  <\/jats:p>","DOI":"10.1038\/s41368-023-00252-1","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T23:25:17Z","timestamp":1696893917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH)"],"prefix":"10.1038","volume":"15","author":[{"given":"Kelsey A.","family":"Carpenter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia O.","family":"Alkhatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan A.","family":"Dulion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Guirado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1266-8599","authenticated-orcid":false,"given":"Shreya","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-234X","authenticated-orcid":false,"given":"Ryan D.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"252_CR1","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter, T. O., Imel, E. A., Holm, I. A., Jan de Beur, S. M. & Insogna, K. L. A clinician\u2019s guide to X-linked hypophosphatemia. J. Bone Min. Res 26, 1381\u20131388 (2011).","journal-title":"J. Bone Min. Res"},{"key":"252_CR2","doi-asserted-by":"crossref","first-page":"E1636","DOI":"10.1152\/ajpendo.00396.2007","volume":"293","author":"S Liu","year":"2007","unstructured":"Liu, S., Tang, W., Zhou, J., Vierthaler, L. & Quarles, L. D. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am. J. Physiol. Endocrinol. Metab. 293, E1636\u2013E1644 (2007).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"252_CR3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/0022034520901719","volume":"99","author":"H Zhang","year":"2020","unstructured":"Zhang, H. et al. Dentoalveolar Defects in the Hyp Mouse Model of X-linked Hypophosphatemia. J. Dent. Res 99, 419\u2013428 (2020).","journal-title":"J. Dent. Res"},{"key":"252_CR4","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1096\/fj.10-177816","volume":"25","author":"A Martin","year":"2011","unstructured":"Martin, A. et al. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J. 25, 2551\u20132562 (2011).","journal-title":"FASEB J."},{"key":"252_CR5","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1210\/me.2012-1062","volume":"26","author":"A Martin","year":"2012","unstructured":"Martin, A. et al. Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice. Mol. Endocrinol. 26, 1883\u20131895 (2012).","journal-title":"Mol. Endocrinol."},{"key":"252_CR6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bone.2016.11.019","volume":"95","author":"T Boukpessi","year":"2017","unstructured":"Boukpessi, T. et al. Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia. Bone 95, 151\u2013161 (2017).","journal-title":"Bone"},{"key":"252_CR7","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/jbmr.1766","volume":"28","author":"NM Barros","year":"2013","unstructured":"Barros, N. M. et al. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia. J. Bone Min. Res 28, 688\u2013699 (2013).","journal-title":"J. Bone Min. Res"},{"key":"252_CR8","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/jbmr.4101","volume":"35","author":"B Hoac","year":"2020","unstructured":"Hoac, B. et al. Genetic Ablation of Osteopontin in Osteomalacic Hyp Mice Partially Rescues the Deficient Mineralization Without Correcting Hypophosphatemia. J. Bone Miner. Res. 35, 2032\u20132048 (2020).","journal-title":"J. Bone Miner. Res."},{"key":"252_CR9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13005-019-0192-x","volume":"15","author":"M Hanisch","year":"2019","unstructured":"Hanisch, M., Bohner, L., Sabandal, M. M. I., Kleinheinz, J. & Jung, S. Oral symptoms and oral health-related quality of life of individuals with x-linked hypophosphatemia. Head. Face Med. 15, 8 (2019).","journal-title":"Head. Face Med."},{"key":"252_CR10","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","volume":"3","author":"A Skrinar","year":"2019","unstructured":"Skrinar, A. et al. The Lifelong Impact of X-Linked Hypophosphatemia: Results From a Burden of Disease Survey. J. Endocr. Soc. 3, 1321\u20131334 (2019).","journal-title":"J. Endocr. Soc."},{"key":"252_CR11","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/0022034516677528","volume":"96","author":"M Biosse Duplan","year":"2017","unstructured":"Biosse Duplan, M. et al. Phosphate and Vitamin D Prevent Periodontitis in X-Linked Hypophosphatemia. J. Dent. Res 96, 388\u2013395 (2017).","journal-title":"J. Dent. Res"},{"key":"252_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2013-1009","volume":"35","author":"BL Foster","year":"2014","unstructured":"Foster, B. L., Nociti, F. H. Jr & Somerman, M. J. The rachitic tooth. Endocr. Rev. 35, 1\u201334 (2014).","journal-title":"Endocr. Rev."},{"key":"252_CR13","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1902\/jop.2009.090129","volume":"80","author":"H Fong","year":"2009","unstructured":"Fong, H. et al. Aberrant cementum phenotype associated with the hypophosphatemic hyp mouse. J. Periodontol. 80, 1348\u20131354 (2009).","journal-title":"J. Periodontol."},{"key":"252_CR14","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","volume":"23","author":"X Li","year":"2008","unstructured":"Li, X. et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res. 23, 860\u2013869 (2008).","journal-title":"J. Bone Miner. Res."},{"key":"252_CR15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ijos.2014.12","volume":"6","author":"U Kuchler","year":"2014","unstructured":"Kuchler, U. et al. Dental and periodontal phenotype in sclerostin knockout mice. Int J. Oral. Sci. 6, 70\u201376 (2014).","journal-title":"Int J. Oral. Sci."},{"key":"252_CR16","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","volume":"199","author":"RL van Bezooijen","year":"2004","unstructured":"van Bezooijen, R. L. et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 199, 805\u2013814 (2004).","journal-title":"J. Exp. Med."},{"key":"252_CR17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.aanat.2012.02.014","volume":"194","author":"SD Lehnen","year":"2012","unstructured":"Lehnen, S. D., G\u00f6tz, W., Baxmann, M. & J\u00e4ger, A. Immunohistochemical evidence for sclerostin during cementogenesis in mice. Ann. Anat. 194, 415\u2013421 (2012).","journal-title":"Ann. Anat."},{"key":"252_CR18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1600-0765.2009.01227.x","volume":"45","author":"A Jager","year":"2010","unstructured":"Jager, A., Gotz, W., Lossdorfer, S. & Rath-Deschner, B. Localization of SOST\/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro. J. Periodontal. Res 45, 246\u2013254 (2010).","journal-title":"J. Periodontal. Res"},{"key":"252_CR19","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/jcpe.13624","volume":"49","author":"YS Nam","year":"2022","unstructured":"Nam, Y. S. et al. Sclerostin in periodontal ligament: Homeostatic regulator in biophysical force-induced tooth movement. J. Clin. Periodontol. 49, 932\u2013944 (2022).","journal-title":"J. Clin. Periodontol."},{"key":"252_CR20","doi-asserted-by":"crossref","first-page":"116201","DOI":"10.1016\/j.bone.2021.116201","volume":"154","author":"KA Carpenter","year":"2021","unstructured":"Carpenter, K. A. et al. Sclerostin antibody improves phosphate metabolism hormones, bone formation rates, and bone mass in adult Hyp mice. Bone 154, 116201 (2021).","journal-title":"Bone"},{"key":"252_CR21","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/jbmr.3923","volume":"35","author":"KA Carpenter","year":"2020","unstructured":"Carpenter, K. A. & Ross, R. D. Sclerostin Antibody Treatment Increases Bone Mass and Normalizes Circulating Phosphate Levels in Growing Hyp Mice. J. Bone Min. Res 35, 596\u2013607 (2020).","journal-title":"J. Bone Min. Res"},{"key":"252_CR22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/03008209609029192","volume":"35","author":"MD McKee","year":"1996","unstructured":"McKee, M. D. & Nanci, A. Osteopontin: an interfacial extracellular matrix protein in mineralized tissues. Connect Tissue Res 35, 197\u2013205 (1996).","journal-title":"Connect Tissue Res"},{"key":"252_CR23","unstructured":"George, A., Guirado, E. & Chen, Y. in Biomineralization. (eds K Endo, T Kogure & H Nagasawa) 137\u2013145 (Springer Singapore)."},{"key":"252_CR24","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1177\/00220345211011041","volume":"100","author":"EJ Lira dos Santos","year":"2021","unstructured":"Lira dos Santos, E. J. et al. Effects of Active Vitamin D or FGF23 Antibody on Hyp Mice Dentoalveolar Tissues. J. Dent. Res. 100, 1482\u20131491 (2021).","journal-title":"J. Dent. Res."},{"key":"252_CR25","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel, E. A. et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 393, 2416\u20132427 (2019).","journal-title":"Lancet"},{"key":"252_CR26","first-page":"e10672","volume":"6","author":"M Gadion","year":"2022","unstructured":"Gadion, M. et al. Burosumab and Dental Abscesses in Children With X-Linked Hypophosphatemia. JBMR 6, e10672 (2022).","journal-title":"JBMR"},{"key":"252_CR27","doi-asserted-by":"crossref","first-page":"e3241","DOI":"10.1210\/clinem\/dgac296","volume":"107","author":"LM Ward","year":"2022","unstructured":"Ward, L. M. et al. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia. J. Clin. Endocrinol. Metab. 107, e3241\u2013e3253 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"252_CR28","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1073\/pnas.73.12.4667","volume":"73","author":"EM Eicher","year":"1976","unstructured":"Eicher, E. M., Southard, J. L., Scriver, C. R. & Glorieux, F. H. Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc. Natl Acad. Sci. USA 73, 4667\u20134671 (1976).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"252_CR29","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bone.2017.07.026","volume":"103","author":"BR Coyac","year":"2017","unstructured":"Coyac, B. R. et al. Tissue-specific mineralization defects in the periodontium of the Hyp mouse model of X-linked hypophosphatemia. Bone 103, 334\u2013346 (2017).","journal-title":"Bone"},{"key":"252_CR30","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1601-0825.2006.01326.x","volume":"13","author":"C Chaussain-Miller","year":"2007","unstructured":"Chaussain-Miller, C. et al. Dentin structure in familial hypophosphatemic rickets: benefits of vitamin D and phosphate treatment. Oral. Dis. 13, 482\u2013489 (2007).","journal-title":"Oral. Dis."},{"key":"252_CR31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1365-263X.1998.00059.x","volume":"8","author":"JR Goodman","year":"1998","unstructured":"Goodman, J. R., Gelbier, M. J., Bennett, J. H. & Winter, G. B. Dental problems associated with hypophosphataemic vitamin D resistant rickets. Int J. Paediatr. Dent. 8, 19\u201328 (1998).","journal-title":"Int J. Paediatr. Dent."},{"key":"252_CR32","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1902\/jop.2011.100736","volume":"82","author":"L Ye","year":"2011","unstructured":"Ye, L., Liu, R., White, N., Alon, U. S. & Cobb, C. M. Periodontal status of patients with hypophosphatemic rickets: a case series. J. Periodontol. 82, 1530\u20131535 (2011).","journal-title":"J. Periodontol."},{"key":"252_CR33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2106\/JBJS.N.00654","volume":"97","author":"AS Virdi","year":"2015","unstructured":"Virdi, A. S. et al. Sclerostin antibody treatment improves implant fixation in a model of severe osteoporosis. J. Bone Jt. Surg. Am. 97, 133\u2013140 (2015).","journal-title":"J. Bone Jt. Surg. Am."},{"key":"252_CR34","doi-asserted-by":"crossref","first-page":"20794","DOI":"10.1074\/jbc.M311131200","volume":"279","author":"M El-Tanani","year":"2004","unstructured":"El-Tanani, M., Platt-Higgins, A., Rudland, P. S. & Campbell, F. C. Ets gene PEA3 cooperates with beta-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription. J. Biol. Chem. 279, 20794\u201320806 (2004).","journal-title":"J. Biol. Chem."},{"key":"252_CR35","doi-asserted-by":"crossref","first-page":"14117","DOI":"10.1074\/jbc.M808337200","volume":"284","author":"MS Friedman","year":"2009","unstructured":"Friedman, M. S., Oyserman, S. M. & Hankenson, K. D. Wnt11 promotes osteoblast maturation and mineralization through R-spondin 2. J. Biol. Chem. 284, 14117\u201314125 (2009).","journal-title":"J. Biol. Chem."},{"key":"252_CR36","doi-asserted-by":"crossref","unstructured":"Tokavanich, N., Wein, M. N., English, J. D., Ono, N. & Ono, W. The Role of Wnt Signaling in Postnatal Tooth Root Development. Front. Dent. Med. 2, 769134 (2021)","DOI":"10.3389\/fdmed.2021.769134"},{"key":"252_CR37","doi-asserted-by":"crossref","unstructured":"Jarvinen, E., Shimomura-Kuroki, J., Balic, A., Jussila, M. & Thesleff, I. Mesenchymal Wnt\/beta-catenin signaling limits tooth number. Development 145, (2018)","DOI":"10.1242\/dev.158048"},{"key":"252_CR38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5115\/acb.2012.45.3.193","volume":"45","author":"TH Kim","year":"2012","unstructured":"Kim, T. H. et al. Col1a1-cre mediated activation of \u03b2-catenin leads to aberrant dento-alveolar complex formation. Anat. Cell Biol. 45, 193\u2013202 (2012).","journal-title":"Anat. Cell Biol."},{"key":"252_CR39","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bbrc.2011.07.116","volume":"412","author":"TH Kim","year":"2011","unstructured":"Kim, T. H. et al. Constitutive stabilization of \u00df-catenin in the dental mesenchyme leads to excessive dentin and cementum formation. Biochem Biophys. Res Commun. 412, 549\u2013555 (2011).","journal-title":"Biochem Biophys. Res Commun."},{"key":"252_CR40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.matbio.2015.12.009","volume":"52-54","author":"Y Ren","year":"2016","unstructured":"Ren, Y. et al. Sclerostin antibody (Scl-Ab) improves osteomalacia phenotype in dentin matrix protein 1(Dmp1) knockout mice with little impact on serum levels of phosphorus and FGF23. Matrix Biol. 52-54, 151\u2013161 (2016).","journal-title":"Matrix Biol."},{"key":"252_CR41","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1073\/pnas.1221255110","volume":"110","author":"ZC Ryan","year":"2013","unstructured":"Ryan, Z. C. et al. Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc. Natl Acad. Sci. USA 110, 6199\u20136204 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"252_CR42","doi-asserted-by":"crossref","first-page":"e871","DOI":"10.1210\/clinem\/dgz203","volume":"105","author":"S Hawley","year":"2020","unstructured":"Hawley, S. et al. Prevalence and Mortality of Individuals With X-Linked Hypophosphatemia: A United Kingdom Real-World Data Analysis. J. Clin. Endocrinol. Metab. 105, e871\u2013e878 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"252_CR43","doi-asserted-by":"crossref","unstructured":"Laurent, M. R. et al. Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium. Front. Endocrinol. 12, 641543 (2021).","DOI":"10.3389\/fendo.2021.641543"},{"key":"252_CR44","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/EJE-15-0515","volume":"174","author":"S Rafaelsen","year":"2016","unstructured":"Rafaelsen, S., Johansson, S., R\u00e6der, H. & Bjerknes, R. Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications. Eur. J. Endocrinol. 174, 125\u2013136 (2016).","journal-title":"Eur. J. Endocrinol."},{"key":"252_CR45","doi-asserted-by":"crossref","first-page":"1087761","DOI":"10.3389\/froh.2023.1087761","volume":"4","author":"A Larsson","year":"2023","unstructured":"Larsson, A. et al. Dental health of patients with X-linked hypophosphatemia: A controlled study. Front Oral. Health 4, 1087761 (2023).","journal-title":"Front Oral. Health"},{"key":"252_CR46","doi-asserted-by":"crossref","unstructured":"Padhi, D. et al. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study. J Clin Pharmacol, (2013).","DOI":"10.1002\/jcph.239"},{"key":"252_CR47","doi-asserted-by":"crossref","first-page":"705505","DOI":"10.3389\/fgene.2021.705505","volume":"12","author":"M Cardinal","year":"2021","unstructured":"Cardinal, M. et al. Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse. Front Genet 12, 705505 (2021).","journal-title":"Front Genet"},{"key":"252_CR48","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jbmr.3038","volume":"32","author":"SW Kim","year":"2017","unstructured":"Kim, S. W. et al. Sclerostin antibody administration converts bone lining cells into active osteoblasts. J. Bone Miner. Res. 32, 892\u2013901 (2017).","journal-title":"J. Bone Miner. Res."},{"key":"252_CR49","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.yrtph.2016.08.010","volume":"81","author":"L Chouinard","year":"2016","unstructured":"Chouinard, L. et al. Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study. Regul. Toxicol. Pharm. 81, 212\u2013222 (2016).","journal-title":"Regul. Toxicol. Pharm."},{"key":"252_CR50","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/0022034515610768","volume":"95","author":"Y Chen","year":"2016","unstructured":"Chen, Y., Zhang, Y., Ramachandran, A. & George, A. DSPP Is Essential for Normal Development of the Dental-Craniofacial Complex. J. Dent. Res 95, 302\u2013310 (2016).","journal-title":"J. Dent. Res"},{"key":"252_CR51","first-page":"e10474","volume":"5","author":"MB Chavez","year":"2021","unstructured":"Chavez, M. B. et al. Guidelines for Micro\u2013Computed Tomography Analysis of Rodent Dentoalveolar Tissues. JBMR 5, e10474 (2021).","journal-title":"JBMR"},{"key":"252_CR52","doi-asserted-by":"crossref","first-page":"16007","DOI":"10.1117\/1.JBO.19.1.016007","volume":"19","author":"JS Bredfeldt","year":"2014","unstructured":"Bredfeldt, J. S. et al. Computational segmentation of collagen fibers from second-harmonic generation images of breast cancer. J. Biomed. Opt. 19, 16007 (2014).","journal-title":"J. Biomed. Opt."},{"key":"252_CR53","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/03008209909000703","volume":"40","author":"R Srinivasan","year":"1999","unstructured":"Srinivasan, R., Chen, B., Gorski, J. P. & George, A. Recombinant expression and characterization of dentin matrix protein 1. Connect. Tissue Res. 40, 251\u2013258 (1999).","journal-title":"Connect. Tissue Res."}],"container-title":["International Journal of Oral Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41368-023-00252-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41368-023-00252-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41368-023-00252-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T18:01:57Z","timestamp":1700330517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41368-023-00252-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["252"],"URL":"https:\/\/doi.org\/10.1038\/s41368-023-00252-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2762671\/v1","asserted-by":"object"}]},"ISSN":["2049-3169"],"issn-type":[{"value":"2049-3169","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"assertion":[{"value":"31 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declared no potential conflicts of interest with respect to the research and\/or publication of this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}